Abstract
We herein report a patient with type B insulin resistance in whom liraglutide significantly improved postprandial hyperglycemia that had been highly resistant to other treatments, including insulin therapy. The patient was a 73-year-old Japanese male whose hyperglycemia had worsened rapidly after being diagnosed as diabetes. His fasting plasma glucose was 77 mg/dL, HbA1c was 8.6 %, and serum insulin level was 366 /μU/mL. As anti-insulin receptor antibody was detected, we diagnosed the patient with type B insulin resistance. CGM (Continuous Glucose Monitoring) showed that liraglutide reduced the average blood glucose level from 124 mg/dL (standard deviation [SD] 59 mg/dL) to 80 mg/dL (SD 16 mg/dL) by improving the postprandial hyperglycemia and did not increase the time in a hypoglycemic state (27 % to 23 %). The meal tolerance test showed that liraglutide significantly enhanced the reactivity of the plasma insulin responses after food intake. Liraglutide was also effective as a treatment when the patient's postprandial hyperglycemia worsened again, in parallel with increasing inhibited insulin receptor rates. Our findings in this case imply the specific effect of liraglutide in improving type B insulin resistance complicated with postprandial hyperglycemia.
| Original language | English |
|---|---|
| Pages (from-to) | 244-252 |
| Number of pages | 9 |
| Journal | Journal of the Japan Diabetes Society |
| Volume | 60 |
| Issue number | 3 |
| Publication status | Published - Jan 1 2017 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Cite this
A case of type B insulin resistance syndrome with postprandial hyperglycemia successfully treated with liraglutide. / Uchida, Satoru; Yamaguchi, Mina; Hasegawa, Hiromi; Ohkiba, Noriaki; Bouchi, Ryotaro; Minami, Isao; Ogawa, Yoshihiro.
In: Journal of the Japan Diabetes Society, Vol. 60, No. 3, 01.01.2017, p. 244-252.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A case of type B insulin resistance syndrome with postprandial hyperglycemia successfully treated with liraglutide
AU - Uchida, Satoru
AU - Yamaguchi, Mina
AU - Hasegawa, Hiromi
AU - Ohkiba, Noriaki
AU - Bouchi, Ryotaro
AU - Minami, Isao
AU - Ogawa, Yoshihiro
PY - 2017/1/1
Y1 - 2017/1/1
N2 - We herein report a patient with type B insulin resistance in whom liraglutide significantly improved postprandial hyperglycemia that had been highly resistant to other treatments, including insulin therapy. The patient was a 73-year-old Japanese male whose hyperglycemia had worsened rapidly after being diagnosed as diabetes. His fasting plasma glucose was 77 mg/dL, HbA1c was 8.6 %, and serum insulin level was 366 /μU/mL. As anti-insulin receptor antibody was detected, we diagnosed the patient with type B insulin resistance. CGM (Continuous Glucose Monitoring) showed that liraglutide reduced the average blood glucose level from 124 mg/dL (standard deviation [SD] 59 mg/dL) to 80 mg/dL (SD 16 mg/dL) by improving the postprandial hyperglycemia and did not increase the time in a hypoglycemic state (27 % to 23 %). The meal tolerance test showed that liraglutide significantly enhanced the reactivity of the plasma insulin responses after food intake. Liraglutide was also effective as a treatment when the patient's postprandial hyperglycemia worsened again, in parallel with increasing inhibited insulin receptor rates. Our findings in this case imply the specific effect of liraglutide in improving type B insulin resistance complicated with postprandial hyperglycemia.
AB - We herein report a patient with type B insulin resistance in whom liraglutide significantly improved postprandial hyperglycemia that had been highly resistant to other treatments, including insulin therapy. The patient was a 73-year-old Japanese male whose hyperglycemia had worsened rapidly after being diagnosed as diabetes. His fasting plasma glucose was 77 mg/dL, HbA1c was 8.6 %, and serum insulin level was 366 /μU/mL. As anti-insulin receptor antibody was detected, we diagnosed the patient with type B insulin resistance. CGM (Continuous Glucose Monitoring) showed that liraglutide reduced the average blood glucose level from 124 mg/dL (standard deviation [SD] 59 mg/dL) to 80 mg/dL (SD 16 mg/dL) by improving the postprandial hyperglycemia and did not increase the time in a hypoglycemic state (27 % to 23 %). The meal tolerance test showed that liraglutide significantly enhanced the reactivity of the plasma insulin responses after food intake. Liraglutide was also effective as a treatment when the patient's postprandial hyperglycemia worsened again, in parallel with increasing inhibited insulin receptor rates. Our findings in this case imply the specific effect of liraglutide in improving type B insulin resistance complicated with postprandial hyperglycemia.
UR - http://www.scopus.com/inward/record.url?scp=85017021537&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017021537&partnerID=8YFLogxK
M3 - Article
VL - 60
SP - 244
EP - 252
JO - Journal of the Japan Diabetes Society
JF - Journal of the Japan Diabetes Society
SN - 0021-437X
IS - 3
ER -